Cancer - Arcellx, Inc.

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05396885

A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Drug

CART-ddBCMA

Condition

Multiple Myeloma